Other Oncology.TV sites:
Home
Continuing Education
Symptom Management
Login
|
Acquired Resistance in Lung Cancer
Patient Forum
for ALK, ROS1 & EGFR Patients & Caregivers
Speaker Slides
Leveraging Patient Engagement & the Role of Advocacy
- Bonnie J. Addario
Clinical Trial Design and Development of Highly Targeted Agents in the Molecular Oncology Era
- Gideon Blumenthal, MD
The Expanding Role of Patient Self-Education & Online Communities in Molecularly Defined Subgroups
- Craig In PA
Mechanisms of ALK Resistance & Implications for Treatment
- Robert C. Doebele, MD, PhD
Repeat Biopsies and the Potential Value of Biologically-Informed Acquired Resistance Therapy
- Lecia V. Sequist, MD, MPH
Novel EGFR Inhibitors in the Setting of Acquired Resistance
- Pasi A. Jänne, MD, PhD
Combinations for Treating EGFR Acquired Resistance
- Melissa L. Johnson, MD
Using Non-targeted Therapies in Targeted Lung Cancer Populations
- Nathan Pennell, M.D., Ph.D.
What is Acquired Resistance and How Does it Occur?
- Gregory J. Riely, M.D.
Current and Emerging Approaches to Acquired Resistance for ALK/ROS1
- Alice T. Shaw, MD PhD
Life After Erlotinib: What Next?
- Jared Weiss
Cost of & Access to Molecularly Targeted Therapies as Barriers to Optimal Care
- H. Jack West, MD
Privacy Statement
|
Terms Of Use
|
Contact Oncology.TV
|
Copyright 2024 by Oncology.TV